Part of CASE WESTERN RESERVE UNIVERSITY
Clinical Trials
492
31 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1826
Active, not recruiting
17
3.5%
Completed
265
53.9%
Enrolling By Invitation
1
0.2%
Not yet recruiting
13
2.6%
Recruiting
47
9.6%
Suspended
4
0.8%
Terminated
68
13.8%
Withdrawn
77
15.7%
No approval data available
- The University of Kentucky Markey Cancer Center became the first U.S. site to treat a patient with Alveltamig (ZG006), a novel trispecific T-cell engager immunotherapy for small cell lung cancer in late October. - Alveltamig features an enhanced design with three binding arms compared to FDA-approved bispecific tarlatamab, potentially offering stronger cancer cell-immune cell connections for patients whose disease has progressed. - The first patient experienced no side effects from initial dosing and tolerated a second treatment well, with the therapy showing potential activity against brain metastases common in small cell lung cancer. - The Phase 1 trial follows successful tolerability data from China and will enroll patients at six U.S. sites to evaluate this next-generation immunotherapy approach.
- Only 16% of high-risk myelodysplastic syndrome patients receive indicated hypomethylating agent therapy, despite guidelines recommending treatment for all patients in this category. - Younger, white, male patients are significantly more likely to receive treatment, while patients over 74, females, and Black patients face substantial disparities in access to care. - Half of treated patients discontinue therapy by cycle 6 and fail to complete minimum recommended treatment cycles, compromising therapeutic outcomes. - The study analyzed 7,935 Medicare patients and found widespread non-adherence to established treatment guidelines across multiple demographic groups.
